Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Antiviral Research|December 31, 2023
Current state and challenges in respiratory syncytial virus drug discovery and developmentGang Zou, Sushan Cao, Zhao Gao, et al.
Molecular Cancer Therapeutics|March 17, 2007
Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2Luigi Carlessi, Giacomo Buscemi, Gary Larson, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2006
Identification of novel, selective and potent Chk2 inhibitorsGary Larson, Shunqi Yan, Huanming Chen, et al.
Journal of Medicinal Chemistry|April 15, 2005
Design, synthesis, and antiviral activity of adenosine 5'-phosphonate analogues as chain terminators against hepatitis C virusYung-hyo Koh, Jae Hoon Shim, Jim Zhen Wu, et al.
Plos Pathogens|January 23, 2026
Molecular mechanism of ziresovir targeting the fusion glycoprotein of respiratory syncytial virusMengrong Yan, Jingjing Zou, Zhao Gao, et al.
The Journal of Biological Chemistry|October 20, 2001
Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymeraseDarius Moradpour, Elke Bieck, Thomas Hügle, et al.
Molecular Cancer Therapeutics|May 21, 2013
Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinomaArthur Kwok Leung Cheung, Joseph Chok Yan Ip, Hong Lok Lung, et al.
Molecular Cell|June 11, 2011
The molecular basis of ABA-independent inhibition of PP2Cs by a subclass of PYL proteinsQi Hao, Ping Yin, Wenqi Li, et al.
Journal of Medicinal Chemistry|October 20, 2018
Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion InhibitorsXiufang Zheng, Chungen Liang, Lisha Wang, et al.
Pageof 3